The Women's Health Questionnaire (WHQ): Frequently Asked Questions (FAQ)

Overview

Journal Health Qual Life Outcomes

Publisher Biomed Central

Specialty Public Health

Date 2003 Oct 3

PMID 14521718

Citations 27

Authors

Myra S Hunter

Affiliations

Soon will be listed here.

Abstract

The Women's Health Questionnaire (WHQ) is a measure of mid-aged women's emotional and physical health. Since its publication in 1992 the WHQ has been widely used in multinational clinical trials, in epidemiological studies as well as in the evaluation of non-medical treatments. In particular the WHQ has been included as a quality of life measure in trials of hormonal preparations for peri and post menopausal women and in studies using a variety of preventative interventions for mid-aged and older women. The questionnaire was developed in English and standardised on a sample of women aged 45-65 years. It is reliable, has good concurrent validity and is sensitive to detecting change, and is available in 27 languages. The range of subscales included in the WHQ enable a detailed assessment of dimensions of emotional and physical health, such as depression, anxiety, sleep problems, somatic symptoms, with optional subscales for menstrual problems and sexual difficulties. The WHQ is the first measure to be included in the MAPI Research Institute's database, the International Health-related Quality of Life Outcomes Database (IQOD). Drawing upon data from international studies this project aims to produce reference values for cross-culturally valid, reliable and responsive quality of life instruments. In addition to this work, a revised shorter version of the WHQ is currently being developed.

Citing Articles

Breast and endometrial safety of micronised progesterone versus norethisterone acetate in menopausal hormone therapy (PROBES): study protocol of a double-blind randomised controlled trial.

Lundell C, Stergiopoulos N, Blomberg L, Ujvari D, Schuppe-Koistinen I, Kopp-Kallner H BMJ Open. 2024; 14(10):e082749.

PMID: 39448218 PMC: 11499784. DOI: 10.1136/bmjopen-2023-082749.

A 2-year follow-up to a randomized controlled trial on resistance training in postmenopausal women: vasomotor symptoms, quality of life and cardiovascular risk markers.

Nilsson S, Henriksson M, Hammar M, Berin E, Lawesson S, Ward L BMC Womens Health. 2024; 24(1):511.

PMID: 39272114 PMC: 11396825. DOI: 10.1186/s12905-024-03351-1.

[Study to improve the quality of life in perimenopausal women from the community pharmacy. Research protocol pilot study -m+45].

Prado Alvarez A, Mera Gallego I, Climent Catala M, Andraca Iturbe L, Caelles Franch N, Conde Babarro M Farm Comunitarios. 2024; 16(3):12-23.

PMID: 39188783 PMC: 11346263. DOI: 10.33620/FC.2173-9218.(2024).16.

Mapping global prevalence of menopausal symptoms among middle-aged women: a systematic review and meta-analysis.

Fang Y, Liu F, Zhang X, Chen L, Liu Y, Yang L BMC Public Health. 2024; 24(1):1767.

PMID: 38956480 PMC: 11220992. DOI: 10.1186/s12889-024-19280-5.

Validation of the Brazilian 10-item Cervantes Scale for the assessment of menopausal symptoms.

DallAgno M, Ferreira C, Ferreira F, Teichmann P, Zandona J, Perez-Lopez F Rev Bras Ginecol Obstet. 2024; 46.

PMID: 38765526 PMC: 11075430. DOI: 10.61622/rbgo/2024AO07.

References

Bebbington P, Hurry J, Tennant C, Sturt E, Wing J . Epidemiology of mental disorders in Camberwell. Psychol Med. 1981; 11(3):561-79. DOI: 10.1017/s0033291700052879. View

Nathorst-Boos J, Wiklund I, Mattsson L, Sandin K, von Schoultz B . Is sexual life influenced by transdermal estrogen therapy? A double blind placebo controlled study in postmenopausal women. Acta Obstet Gynecol Scand. 1993; 72(8):656-60. DOI: 10.3109/00016349309021160. View

Strickler R, Stovall D, Merritt D, Shen W, Wong M, Silfen S . Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol. 2000; 96(3):359-65. DOI: 10.1016/s0029-7844(00)00937-6. View

Shulman L, Yankov V, Uhl K . Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized,.... Menopause. 2002; 9(3):195-207. DOI: 10.1097/00042192-200205000-00008. View

Genazzani A, Nicolucci A, Campagnoli C, Crosignani P, Nappi C, Serra G . Validation of Italian version of the Women's Health Questionnaire: assessment of quality of life of women from the general population and those attending menopause centers. Climacteric. 2002; 5(1):70-7. View

Ryan N, Rosner A . Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women. Clin Ther. 2001; 23(7):1099-115. DOI: 10.1016/s0149-2918(01)80094-1. View

Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G . Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas. 2003; 44(2):157-63. DOI: 10.1016/s0378-5122(02)00327-4. View

Murphy E . Severity of psychiatric disorder and the 30-item general health questionnaire. Br J Psychiatry. 1979; 134:609-16. DOI: 10.1192/bjp.134.6.609. View

Liao K, Hunter M . Preparation for menopause: prospective evaluation of a health education intervention for mid-aged women. Maturitas. 1998; 29(3):215-24. DOI: 10.1016/s0378-5122(98)00033-4. View

10.

Wiklund I, Karlberg J, Mattsson L . Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol. 1993; 168(3 Pt 1):824-30. DOI: 10.1016/s0002-9378(12)90828-5. View

11.

Wool C, Cerutti R, Marquis P, Cialdella P, Hervie C . Psychometric validation of two Italian quality of life questionnaires in menopausal women. Maturitas. 2000; 35(2):129-42. DOI: 10.1016/s0378-5122(00)00093-1. View

12.

Fitzpatrick L, Pace C, Wiita B . Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med. 2000; 9(4):381-7. DOI: 10.1089/15246090050020691. View

13.

Williamson J, White A, Hart A, Ernst E . Randomised controlled trial of reflexology for menopausal symptoms. BJOG. 2002; 109(9):1050-5. DOI: 10.1111/j.1471-0528.2002.01504.x. View

14.

Voss S, Quail D, Dawson A, Backstrom T, Aguas F, Erenus M . A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG. 2002; 109(8):874-85. DOI: 10.1111/j.1471-0528.2002.01510.x. View

15.

Hunter M . The south-east England longitudinal study of the climacteric and postmenopause. Maturitas. 1992; 14(2):117-26. DOI: 10.1016/0378-5122(92)90004-n. View

16.

Vickers M, Martin J, Meade T . The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. BMC Womens Health. 2007; 7:2. PMC: 1828722. DOI: 10.1186/1472-6874-7-2. View

17.

Slaven L, Lee C . Mood and symptom reporting among middle-aged women: the relationship between menopausal status, hormone replacement therapy, and exercise participation. Health Psychol. 1997; 16(3):203-8. DOI: 10.1037//0278-6133.16.3.203. View

18.

SNAITH R, Bridge G, Hamilton M . The Leeds scales for the self-assessment of anxiety and depression. Br J Psychiatry. 1976; 128:156-65. DOI: 10.1192/bjp.128.2.156. View

19.

Slaven L, Lee C . A Cross-sectional Survey of Menopausal Status, Symptoms and Psychological Distress in a Community Sample of Australian Women. J Health Psychol. 2011; 3(1):117-23. DOI: 10.1177/135910539800300109. View

20.

Mairon N, JOYCE C, Le Gal M . Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol. 1994; 170(2):618-24. DOI: 10.1016/s0002-9378(94)70239-x. View